Scholarlink

<p>In 2023, the Italian healthcare system launched HCV screening targeting subjects born in 1968–1989. However, subjects &gt; 50 yrs also need screening. In addition, existence of gender gaps in HCV diagnosis and treatment has been suggested. Our aim was to identify undiagnosed individuals outside the age groups to whom the screening is offered and to gather data about gender gaps. This is a prospective, opportunistic micro-elimination initiative based on a network between 24 Apulian pharmacies and our center. Between 01/07/2022 and 01/03/2024, subjects aged 55 to 85, accessing pharmacies were offered HCVOraQuick tests (F/M 1:1) and administered ad-hoc questionnaires. In total, 13,042 screening were carried out. Mean age was 64.9 (± 7.6), 51.1% females. Overall, 1.1% were anti-HCV positive: mean age 68.3 (± 10.3), 44.9% females. Seroprevalence was higher in males (<i>p</i> &lt; 0.00001), elderly (<i>p</i> &lt; 0.00001) and unknown transmission route (<i>p</i> = 0.0009). HCV-RNA was detectable in 67.4% of seropositive. They were 67.5 (± 10.7) yrs old, mainly males (55.1%). HCV-RNA prevalence was 0.8%, higher in elderly (<i>p</i> = 0.0003) and unknown transmission route (<i>p</i> = 0.0007). Overall, 90% were linked-to-treatment. Differences in patients profiles should be considered to guide policy and more inclusive treatment approaches. Gender differences in screening response and rates of active infections underscore the need for gender-targeted intervention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Micro-elimination initiative for hepatitis C screening: insight into gender gaps and undiagnosed individuals

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月18日

查看全文
  • Annarita Valeria Piazzolla,
  • Domenico Resta,
  • Massimo Greco,
  • Vito Comes,
  • Teresa Vassalli,
  • Federico Mengoli,
  • Elvira Memoli,
  • Donato Checchia,
  • Nazario Migliorelli,
  • Giovanni Giuliani,
  • Giuditta Giannattasio,
  • Rosaria Maria Checchia,
  • Antonia Giannone,
  • Attilio Noya,
  • Domenico Pugliese,
  • Cristina Carrisi,
  • Grazia Murgo,
  • Vito Carretta,
  • Leonardo Gentile,
  • Lorenzo Ongaro,
  • Giacomo Parisi,
  • Domenico Costantino,
  • Amedeo Giubba,
  • Maria Maddalena Squillante,
  • Alessandra Mangia

摘要

In 2023, the Italian healthcare system launched HCV screening targeting subjects born in 1968–1989. However, subjects > 50 yrs also need screening. In addition, existence of gender gaps in HCV diagnosis and treatment has been suggested. Our aim was to identify undiagnosed individuals outside the age groups to whom the screening is offered and to gather data about gender gaps. This is a prospective, opportunistic micro-elimination initiative based on a network between 24 Apulian pharmacies and our center. Between 01/07/2022 and 01/03/2024, subjects aged 55 to 85, accessing pharmacies were offered HCVOraQuick tests (F/M 1:1) and administered ad-hoc questionnaires. In total, 13,042 screening were carried out. Mean age was 64.9 (± 7.6), 51.1% females. Overall, 1.1% were anti-HCV positive: mean age 68.3 (± 10.3), 44.9% females. Seroprevalence was higher in males (p < 0.00001), elderly (p < 0.00001) and unknown transmission route (p = 0.0009). HCV-RNA was detectable in 67.4% of seropositive. They were 67.5 (± 10.7) yrs old, mainly males (55.1%). HCV-RNA prevalence was 0.8%, higher in elderly (p = 0.0003) and unknown transmission route (p = 0.0007). Overall, 90% were linked-to-treatment. Differences in patients profiles should be considered to guide policy and more inclusive treatment approaches. Gender differences in screening response and rates of active infections underscore the need for gender-targeted intervention.